Purpose: Receptor and subtype discordance between primary breast tumours and metastases is a frequently reported phenomenon. The aim of this article is to review the current evidence on receptor discordance in metastatic breast cancer and to explore the benefit of performing a repeat biopsy in this context.
Methods: Searches were undertaken on PubMed and Clinicaltrials.gov for relevant publications and trials.
Conclusion: The current guidelines recommend offering to perform a biopsy of a metastatic lesion to evaluate receptor status. The choice of systemic therapy in metastatic disease is often based on the receptor status of the primary lesion. As therapeutic decision making is guided by subtype, biopsy of the metastatic lesion to determine receptor status may alter treatment. This article discusses discordance rates, the mechanisms of receptor discordance, the effect of discordance on treatment and survival outcomes, as well as highlighting some ongoing clinical trials in patients with metastatic breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420314 | PMC |
| http://dx.doi.org/10.1007/s10549-024-07431-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlocking breast cancer in Brazilian public health system: Using tissue microarray for accurate immunohistochemical evaluation with limitations in subtyping.
Womens Health (Lond)
January 2025
Department of Pathology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Breast cancer (BC) is a significant burden on healthcare systems, especially in low- and middle-income countries where access to diagnosis and treatment is challenging.
Objectives: The purpose of this study was to assess the diagnostic accuracy and cost using tissue microarray (TMA) instead of traditional immunohistochemical (IHC) evaluation for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), and the proliferation marker Ki-67 and BC subtyping within the Brazilian public health system.
Design: This is a retrospective cohort study comparing TMA slides with traditional whole-slide evaluation for IHC markers in 242 BC cases.
Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
Histopathology
December 2024
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Aims: To evaluate the evolution when breast cancer (BC) is classified as three clinical profiles and five clinical profiles by incorporating human epidermal growth factor 2 (HER2)-low to the biomarkers' profile.
Methods And Results: BC with distant metastasis that has document hormonal receptors (HR) (positive, negative) and HER2 (positive, low, zero) results were included (n = 161). Cases were categorised into three clinical profiles (HR-positive/HER2-negative, HER2-positive and TNBC) and five (HR-positive/HER2-zero, HR-positive/HER2-low, HR-negative/HER2-zero, HR-negative/HER2-low, HR-positive or negative/HER2-positive).
Discordance in biomarker expression between primary breast cancers and loco-regional recurrences: a comprehensive analysis of 112 cases.
Gland Surg
November 2024
Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Background: Breast cancer is a complex disease encompassing multiple phenotypic and genetic subtypes. The biomarker status of primary and recurrent lesions may be dissimilar, and changes in biomarker status may inform clinical decision-making. The expression of biomarkers between primary breast cancers and loco-regional recurrences lacked large sample studies.
View Article and Find Full Text PDFGrowth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology, Odense University Hospital, Odense, Denmark.
Growth hormone (GH) is the key regulator of insulin-like growth factor I (IGF-I) generation in healthy states. However, portal insulin delivery is also an essential co-player in the regulation of the GH/IGF-I axis by affecting and regulating hepatic GH receptor synthesis, and subsequently altering hepatic GH sensitivity and IGF-I generation. Disease states of GH excess (e.
View Article and Find Full Text PDFTumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes.
Blood
December 2024
Moffitt Cancer Center, Tampa, Florida, United States.
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are now available. Identifying biomarkers that can predict therapeutic outcomes is crucial for optimizing patient selection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!